TY - JOUR
T1 - Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma
T2 - Extended 4-year follow-up of the phase III CheckMate 214 trial
AU - Albiges, Laurence
AU - Tannir, Nizar M.
AU - Burotto, Mauricio
AU - McDermott, David
AU - Plimack, Elizabeth R.
AU - Barthélémy, Philippe
AU - Porta, Camillo
AU - Powles, Thomas
AU - Donskov, Frede
AU - George, Saby
AU - Kollmannsberger, Christian K.
AU - Gurney, Howard
AU - Grimm, Marc Oliver
AU - Tomita, Yoshihiko
AU - Castellano, Daniel
AU - Rini, Brian I.
AU - Choueiri, Toni K.
AU - Saggi, Shruti Shally
AU - McHenry, M. Brent
AU - Motzer, Robert J.
N1 - Publisher Copyright:
©
PY - 2020/11/27
Y1 - 2020/11/27
N2 - Purpose To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-Term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). Methods Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk and randomised to NIVO (3 mg/kg) plus IPI (1 mg/kg) every three weeks ×4 doses, followed by NIVO (3 mg/kg) every two weeks; or SUN (50 mg) once per day ×4 weeks (6-week cycle). Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiology review committee in patients with intermediate/poor-risk disease (I/P; primary), intent-To-Treat patients (ITT; secondary) and in patients with favourable-risk disease (FAV; exploratory). Results Overall, 1096 patients were randomised (ITT: NIVO+IPI, n=550, SUN, n=546; I/P: NIVO+IPI, n=425, SUN, n=422; FAV: NIVO+IPI, n=125, SUN, n=124). After 4 years minimum follow-up, OS (HR; 95% CI) remained superior with NIVO+IPI vs SUN in ITT (0.69; 0.59 to 0.81) and I/P patients (0.65; 0.54 to 0.78). Four-year PFS probabilities were 31.0% vs 17.3% (ITT) and 32.7% vs 12.3% (I/P), with NIVO+IPI vs SUN. ORR remained higher with NIVO+IPI vs SUN in ITT (39.1% vs 32.4%) and I/P (41.9% vs 26.8%) patients. In FAV patients, the HRs (95% CI) for OS and PFS were 0.93 (0.62 to 1.40) and 1.84 (1.29 to 2.62); ORR was lower with NIVO+IPI vs SUN. However, more patients in all risk groups achieved complete responses with NIVO+IPI: ITT (10.7% vs 2.6%), I/P (10.4% vs 1.4%) and FAV (12.0% vs 6.5%). Probability (95% CI) of response ≥4 years was higher with NIVO+IPI vs SUN (ITT, 59% (0.51 to 0.66) vs 30% (0.21 to 0.39); I/P, 59% (0.50 to 0.67) vs 24% (0.14 to 0.36); and FAV, 60% (0.41 to 0.75) vs 38% (0.22 to 0.54)) regardless of risk category. Safety remained favourable with NIVO+IPI vs SUN. Conclusion After long-Term follow-up, NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety. Trial registration details ClinicalTrials.gov identifier: NCT02231749.
AB - Purpose To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-Term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). Methods Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk and randomised to NIVO (3 mg/kg) plus IPI (1 mg/kg) every three weeks ×4 doses, followed by NIVO (3 mg/kg) every two weeks; or SUN (50 mg) once per day ×4 weeks (6-week cycle). Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiology review committee in patients with intermediate/poor-risk disease (I/P; primary), intent-To-Treat patients (ITT; secondary) and in patients with favourable-risk disease (FAV; exploratory). Results Overall, 1096 patients were randomised (ITT: NIVO+IPI, n=550, SUN, n=546; I/P: NIVO+IPI, n=425, SUN, n=422; FAV: NIVO+IPI, n=125, SUN, n=124). After 4 years minimum follow-up, OS (HR; 95% CI) remained superior with NIVO+IPI vs SUN in ITT (0.69; 0.59 to 0.81) and I/P patients (0.65; 0.54 to 0.78). Four-year PFS probabilities were 31.0% vs 17.3% (ITT) and 32.7% vs 12.3% (I/P), with NIVO+IPI vs SUN. ORR remained higher with NIVO+IPI vs SUN in ITT (39.1% vs 32.4%) and I/P (41.9% vs 26.8%) patients. In FAV patients, the HRs (95% CI) for OS and PFS were 0.93 (0.62 to 1.40) and 1.84 (1.29 to 2.62); ORR was lower with NIVO+IPI vs SUN. However, more patients in all risk groups achieved complete responses with NIVO+IPI: ITT (10.7% vs 2.6%), I/P (10.4% vs 1.4%) and FAV (12.0% vs 6.5%). Probability (95% CI) of response ≥4 years was higher with NIVO+IPI vs SUN (ITT, 59% (0.51 to 0.66) vs 30% (0.21 to 0.39); I/P, 59% (0.50 to 0.67) vs 24% (0.14 to 0.36); and FAV, 60% (0.41 to 0.75) vs 38% (0.22 to 0.54)) regardless of risk category. Safety remained favourable with NIVO+IPI vs SUN. Conclusion After long-Term follow-up, NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety. Trial registration details ClinicalTrials.gov identifier: NCT02231749.
KW - advanced renal cell carcinoma
KW - checkmate 214
KW - dual checkpoint inhibition
KW - long-Term follow-up
KW - nivolumab plus ipilimumab
UR - http://www.scopus.com/inward/record.url?scp=85096947790&partnerID=8YFLogxK
U2 - 10.1136/esmoopen-2020-001079
DO - 10.1136/esmoopen-2020-001079
M3 - Article
C2 - 33246931
AN - SCOPUS:85096947790
SN - 2059-7029
VL - 5
JO - ESMO Open
JF - ESMO Open
IS - 6
M1 - e001079
ER -